X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
https://www.globenewswire.com/news-release/2024/04/09/2859948/0/en/Madrigal-Pharmaceuticals-Announces-U-S-Availability-of-Rezdiffra-resmetirom-for-the-Treatment-of-Patients-with-Noncirrhotic-NASH-with-Moderate-to-Advanced-Liver-Fibrosis.html
https://www.fiercepharma.com/marketing/docs-sing-praises-madrigals-rezdiffra-predict-rapid-uptake
https://www.fiercepharma.com/pharma/after-monumental-mash-nod-its-rezdiffra-madrigal-plots-600m-stock-sale-support-upcoming
https://www.cnbc.com/2024/03/14/fda-approves-nash-liver-disease-drug-from-madrigal-pharmaceuticals.html
https://www.prnewswire.com/news-releases/galmed-announces-grant-of-new-patent-for-the-combination-of-aramchol-with-resmetirom-mgl-3196-rezdiffra-for-the-treatment-of-nash-and-liver-fibrosis-302090340.html
https://www.globenewswire.com//news-release/2024/03/05/2840401/0/en/Madrigal-Pharmaceuticals-Announces-EMA-Validation-of-its-Marketing-Authorization-Application-for-Resmetirom-for-the-Treatment-of-NASH-MASH-with-Liver-Fibrosis.html
https://www.globenewswire.com/news-release/2023/11/10/2778278/0/en/Madrigal-Pharmaceuticals-Presents-New-Data-from-the-Phase-3-MAESTRO-NASH-Trial-Demonstrating-Broad-Treatment-Effects-of-Resmetirom-on-Noninvasive-Measures-of-Liver-Health.html
https://www.fiercebiotech.com/biotech/smooth-sailing-madrigals-nash-candidate-gets-fda-priority-review-no-adcomm
https://ir.madrigalpharma.com/news-releases/news-release-details/madrigal-pharmaceuticals-announces-nda-acceptance-and-priority
https://www.globenewswire.com/news-release/2023/07/17/2705202/0/en/Madrigal-Pharmaceuticals-Completes-Submission-of-New-Drug-Application-Seeking-Accelerated-Approval-of-Resmetirom-for-the-Treatment-of-NASH-with-Liver-Fibrosis.html
https://endpts.com/madrigal-seeks-accelerated-approval-for-experimental-nash-treatment-a-week-after-intercept-rejection/
https://www.globenewswire.com//news-release/2022/12/21/2578247/0/en/Madrigal-Pharmaceuticals-Announces-300-Million-in-Financing-Events-to-Advance-Resmetirom-Program.html
https://www.globenewswire.com/news-release/2022/12/19/2576163/0/en/Madrigal-Announces-Positive-Topline-Results-from-the-Pivotal-Phase-3-MAESTRO-NASH-Clinical-Trial-of-Resmetirom-for-the-Treatment-of-NASH-and-Liver-Fibrosis.html
https://ir.madrigalpharma.com/news-releases/news-release-details/madrigal-pharmaceuticals-announce-topline-results-phase-3-0
https://www.globenewswire.com/news-release/2022/06/25/2469084/0/en/Madrigal-Pharmaceuticals-Presents-Late-Breaking-Phase-3-NASH-Data-and-Multiple-Oral-Abstracts-at-EASL-s-International-Liver-Congress.html
https://www.biopharmadive.com/news/madrigal-nash-fatty-liver-safety-data/618024/
https://www.globenewswire.com/news-release/2022/01/30/2375346/0/en/Madrigal-Pharmaceuticals-To-Announce-Topline-Results-from-the-Phase-3-MAESTRO-NAFLD-1-Study-of-Resmetirom-on-Monday-January-31st.html
https://www.globenewswire.com/news-release/2020/10/01/2102135/0/en/Madrigal-Pharmaceuticals-Announces-Three-Abstracts-Accepted-by-The-Liver-Meeting-Digital-Experience-The-American-Association-for-the-Study-of-Liver-Diseases-Meeting-in-November-202.html
Market Place
Share 
